Accreditation Expired
Multifactorial effects of GLP-1 RAs: A review of the latest evidence
GlobalAn update on the latest clinical data for GLP-1 RAs presented at EASD 2022
Multifactorial effects of GLP-1 RAs: A review of the latest evidence
Recent years have seen significant advances in our understanding of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the emergence of new data and indication updates.
Presented during a satellite symposium at EASD 2022, in this video Prof. John Wilding provides an update on the latest clinical data and discusses the role of GLP-1 RAs in type 2 diabetes management.
Pre-Activity Information
This educational activity is intended for an international audience of non-US and non-UK diabetologists and endocrinologists.
Upon completion of this activity, participants will be able to:
- Recall the results of recent clinical trials for GLP-1 RAs, including CVOTs, and their potential implications for clinical practice
Faculty: Professor John Wilding
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Receipt of grants/research supports | AstraZeneca, NovoNordisk (Institutional) |
| Receipt of honoraria or consultation fees | Alnylam, AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Mundipharma, Pfizer, Rhythm, Saniona, Ysopia (all fees paid to institution) |
| Participation in a company sponsored speaker’s bureau | AstraZeneca, Boehringer Ingelheim |
Staff Disclosures
Liberum IME staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This symposium has been funded by an arms-length educational grant from Novo Nordisk A/S. The content has been developed by the faculty in collaboration with Liberum IME. Novo Nordisk A/S has had no influence on the content or faculty selection.
This module was published on the 25th October 2022.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.